CN107050024A - 用于改善呼吸系统疾病患者睡眠质量的阿地铵 - Google Patents
用于改善呼吸系统疾病患者睡眠质量的阿地铵 Download PDFInfo
- Publication number
- CN107050024A CN107050024A CN201611019750.9A CN201611019750A CN107050024A CN 107050024 A CN107050024 A CN 107050024A CN 201611019750 A CN201611019750 A CN 201611019750A CN 107050024 A CN107050024 A CN 107050024A
- Authority
- CN
- China
- Prior art keywords
- aclidinium
- purposes
- sleep
- respiratory disease
- disease patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Paints Or Removers (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提供了阿地铵或其任何立体异构体或立体异构体的混合物,或其药学上可接受的盐或溶剂合物,用于改善呼吸系统疾病患者的睡眠质量的用途。
Description
本申请是2012年4月11日提交的申请号为PCT/EP2012/056575、发明名称为“用于改善呼吸系统疾病患者睡眠质量的阿地铵”的国际申请的分案申请,所述国际申请于2013年10月15日进入中国国家阶段,其申请号为201280018637.2。
技术领域
本发明涉及阿地铵(aclidinium)的新用途,其可有利地用于改善呼吸系统疾病患者的睡眠质量。
背景技术
例如哮喘和慢性阻塞性肺病(COPD)的呼吸疾病是重大的全球性健康问题,并且全世界的发病率增加。它们通常的特征是气道的炎性功能性障碍,其将导致支气管收缩。
在哮喘中,炎症是由暴露于多种触发因子引起的,所述触发因子包括过敏原和病毒,其既激活了先天性免疫应答和获得性免疫应答的组分。在COPD中,炎症主要是由于暴露于有害颗粒和气体(尤其是香烟烟雾)而发生。COPD这一术语是包括多种疾病,例如慢性支气管炎或肺气肿而不是单一的病理状态。
哮喘和COPD通常伴随严重的由肺部症状引起的身体功能损伤,所述肺部症状例如呼吸困难(呼吸急促)、疲劳、咳嗽、喘鸣、胸闷或充血以及生痰。许多呼吸系统疾病患者抱怨这些症状严重影响他们的睡眠质量。
在COPD患者中,睡眠相关的症状是继呼吸困难和疲劳后第三位的最常报告的症状(Kinsman et al,Chest,1983,83,755-761)。在哮喘中,80%的患者至少偶尔地会因夜间喘鸣和咳嗽而醒来,许多患有严重的稳定期哮喘患者事实上每天夜间都会醒来(Turner-Warwick,M.;Am,J.Med.,1988,85(suppl.1B),6-8)。
呼吸系统疾病患者经常报告的睡眠症状为,例如入睡等待时间较长、保持睡眠困难、经常激醒和觉醒、睡眠浅、总睡眠时间减少、过早醒来且不能再入睡、普遍性失眠以及总体而言非常差的睡眠质量。由早晨呼吸急促引起的日间过度嗜睡和体力活动受限也是睡眠质量下降的常见结果。
这些睡眠紊乱随着疾病的发展将趋于更加严重,并将大幅降低呼吸系统疾病患者的生活质量。
支气管扩张剂,如β-肾上腺素能激动剂或胆碱能毒蕈碱受体拮抗剂(通常称为抗胆碱能剂或抗毒蕈碱剂)通常被医生开给患有阻塞性气道疾病(例如哮喘或COPD)的呼吸系统疾病患者用于吸入。所有可市购的抗胆碱能剂均为合成的托烷衍生物,包括异丙托铵(ipratropium)、氧托铵(oxitropium)、噻托铵(tiotropium)。噻托铵是目前市场上唯一的长效抗胆碱能剂。
众所周知,在呼吸系统疾病患者中,昼夜节律对气道反应性和气道阻力的影响远大于对正常受试者的影响。因此,呼吸系统疾病患者在夜间和清晨特别易于发生支气管收缩,并且这是影响他们睡眠的主要因素。因此,极度需要旨在克服或预防夜间支气管收缩的治疗。但是,Calverley等在Thorax,2003,58(10),855-860的研究表明与仅在早上给药相比,在夜间给予长效支气管扩张剂噻托铵并没有在夜间产生更强的支气管扩张。
现已令人惊讶地发现阿地铵显著地减少了呼吸系统疾病患者中常见的睡眠障碍的发生,因此提高了睡眠质量和整体生活质量。
阿地铵是3(R)-(2-羟基-2,2-二噻吩-2-基乙酰氧基)-1-(3-苯氧基丙基)-1-氮鎓二环[2.2.2]辛烷,其为Almirall开发的长效毒蕈碱受体拮抗剂,用于在呼吸系统疾病(尤其是哮喘和COPD)中通过吸入给药。其首次公开于WO 01/04118。
阿地铵在人血浆中被迅速水解为两种无活性的代谢产物,因此与目前可市购的吸入型抗胆碱能治疗剂相比,其引起全身副作用的可能性降低,并且具有更宽的安全边界。其改善睡眠质量的额外效果是本发明的一个意外的发现。
发明内容
本发明提供了阿地铵,或其任何立体异构体或立体异构体混合物,或其药学上可接受的盐或溶剂合物用于改善呼吸系统疾病患者的睡眠质量的用途。
优选地,阿地铵为带有阴离子X-的盐的形式。最优选地,所述阴离子X-为溴。
在优选的实施方案中,呼吸系统疾病患者患有选自以下的疾病:急性或慢性支气管炎、肺气肿、哮喘和慢性阻塞性肺病,优选哮喘和慢性阻塞性肺病,最优选慢性阻塞性肺病。
在另一个实施方案中,阿地铵作为适于吸入的药物组合物——优选以干粉的形式——给药。所述组合物可通过任意吸入器设备,更优选通过进行给药。
通常,干粉制剂包含选自单糖、二糖或多糖以及糖醇的药学上可接受的载体。优选地,所述载体为乳糖。
阿地铵至少每日给药一次,优选在早上或在夜间给药。更优选阿地铵每日给药两次。在最优选的实施方案中,阿地铵每日给药两次,一次在早上,另一次在夜间。
每次吸入所使用的阿地铵的有效剂量相当于用于吸入的干粉中计量标称剂量为100至1000微克的阿地溴铵,更优选200或400微克的阿地溴铵。
在另一个优选的实施方案中,阿地铵与另外的适于治疗呼吸系统疾病的药物共同给药,所述另外的药物选自例如以下的一种或多种:皮质类固醇、β-肾上腺素能激动剂、PDE4抑制剂、抗组胺剂、抗-IgE抗体、白细胞三烯D4抑制剂、egfr-激酶抑制剂、p38激酶抑制剂和/或NK1-受体拮抗剂。所述另外的药物可与阿地铵存在于相同的药物组合物中或者存在于不同的药物组合物中。优选地,所述另外的药物选自皮质类固醇、β-肾上腺素能激动剂和/或PDE4抑制剂。
阿地铵对呼吸系统疾病患者的睡眠质量的改善可通过观察以下一项或多项的减少和/或总睡眠时间的增加而测量:
a)入睡前的等待时间
b)觉醒总次数
b)早醒
c)维持睡眠的难度
d)浅睡眠
e)失眠
f)日间嗜睡或疲劳
g)早晨期间活动限制。
可能促进阿地铵对呼吸疾病患者睡眠质量改善的临床因素为以下一项或多项睡眠期间的呼吸系统症状的减少:
a)咳嗽严重程度和/或频率
b)生痰
c)喘鸣
d)胸闷
e)胸部充血
f)支气管收缩
g)呼吸急促
h)对救援药物的需要
本发明还提供了用于改善呼吸系统疾病患者睡眠质量的含阿地铵的药物组合物。
本发明还提供了阿地铵在制备用于改善呼吸系统疾病患者睡眠质量的药物中的用途。
本发明还提供了改善呼吸系统疾病患者的睡眠质量的方法,所述方法包括向所述患者给药如上所定义的有效量的阿地铵。
本发明还提供了如上所定义的阿地铵,其用于在患有睡眠障碍的患者中治疗呼吸系统病症,优选哮喘或慢性阻塞性肺病。优选地,所述睡眠障碍包括以下一项或多项:
a)入睡延迟,
b)在夜间醒来一次或多次、优选2次或多于2次、更优选3次或多于3次,
b)早醒,
c)维持睡眠困难,
d)浅睡眠,
e)失眠,
f)日间嗜睡或疲劳,和
g)早晨期间活动受限。
本发明还提供如上所定义的阿地铵在制备用于在患有睡眠障碍的患者中治疗呼吸系统疾病的药物的用途,所述呼吸系统疾病优选哮喘或慢性阻塞性肺病。优选地,所述睡眠障碍包括以下一项或多项:
a)入睡延迟,
b)在夜间醒来一次或多次、优选2次或多于2次、更优选3次或多于3次,
b)早醒,
c)维持睡眠困难,
d)浅睡眠,
e)失眠,
f)日间嗜睡或疲劳,和
g)早晨期间活动受限。
发明详述
通常,阿地铵以带有阴离子X-的盐的形式给药,其中X-为药学上可接受的单价酸或多价酸的阴离子。更常见地,X-为衍生自无机酸或有机酸的阴离子,所述无机酸例如盐酸、氢溴酸、硫酸和磷酸,所述有机酸例如甲磺酸、乙酸、富马酸、琥珀酸、乳酸、柠檬酸或马来酸。最优选地,阿地铵为阿地溴铵的形式。
本发明的化合物既可以未溶剂化的形式存在也可以溶剂化的形式存在。本文中使用术语溶剂合物来描述含有本发明的化合物和一定量一种或多种药学上可接受的溶剂分子的分子配合物。当所述溶剂为水时,使用术语水合物。溶剂合物形式的实例包括但不限于,与水、丙酮、二氯甲烷、2-丙醇、乙醇、甲醇、二甲基亚砜(DMSO)、乙酸乙酯、乙酸、乙醇胺或其混合物结合的本发明化合物。尤其考虑在本发明中的是,一个溶剂分子可与本发明化合物的一个分子结合,例如水合物。
术语“治疗”应理解为包括疾病或病症的症状缓解和/或疾病或病症的病因的消除和/或预防疾病或其症状的出现。
术语“治疗有效量”是指当向需要治疗的患者给药时,足以使治疗起效的量。
阿地铵还可与已知对治疗上述疾病或病症有效的其他药物结合使用。例如,阿地铵可与皮质类固醇或糖皮质激素、β-肾上腺素能激动剂、PDE4抑制剂、抗组胺剂、抗-IGE抗体、白细胞三烯D4拮抗剂、egfr-激酶抑制剂、p38激酶抑制剂和/或NK-1受体激动剂结合。
在本发明中可与阿地铵结合的皮质类固醇具体包括适于在治疗呼吸系统疾病或病症中通过吸入给药的那些,例如,泼尼松龙(prednisolone)、甲泼尼龙(methylprednisolone)、地塞米松、萘非可特(naflocort)、地夫可特(deflazacort)、醋酸卤泼尼松(halopredone acetate)、布地奈德(budesonide)、二丙酸倍氯地米松(beclomethasone dipropionate)、氢化可的松(hydrocortisone)、曲安奈德(triamcinolone acetonide)、氟轻松(fluocinolone acetonide)、醋酸氟轻松(fluocinonide)、氯可托龙(clocortolone Pivalate)、醋丙甲泼尼龙(methylprednisolone aceponate)、软脂酸地塞米松(dexamethasone palmitoate)、替泼尼旦(tipredane)、醋丙氢可的松(hydrocortisone aceponate)、泼尼卡酯(prednicarbate)、双丙酸阿氯米松(alclometasone dipropionate)、卤米松(halometasone)、磺庚甲泼尼龙(methylprednisolone suleptanate)、糠酸莫米松(mometasone furoate)、利美松龙(rimexolone)、法尼基泼尼松龙(prednisolonefarnesylate)、环索奈德(ciclesonide)、地泼罗酮丙酸酯(deprodone propionate)、丙酸氟替卡松(fluticasone propionate)、卤倍他索丙酸酯(halobetasol propionate)、依碳氯替泼诺(loteprednol etabonate)、倍他米松丁酸丙酯(betamethasone butyratepropionate)、氟尼缩松(flunisolide)、泼尼松(prednisone)、地塞米松磷酸钠(dexamethasone sodium phosphate)、曲安西龙(triamcinolone)、倍他米松17-戊酸酯(betamethasone 17-valerate)、倍他米松(betamethasone)、二丙酸倍他米松(betamethasone dipropionate)、醋酸氢化可的松(hydrocortisone acetate)、氢化可的松琥珀酸钠(hydrocortisone sodium succinate)、泼尼松龙磷酸钠(prednisolonesodium phosphate)和丙丁酸氢化可的松(hydrocortisone probutate)。特别优选布地奈德和莫米松(mometasone)。
在本发明中可与阿地铵结合的β-肾上腺素能激动剂具体包括可用于治疗呼吸系统疾病或病症的β2肾上腺素能激动剂,例如,其选自游离形式或药学上可接受的盐形式的阿福特罗(arformoterol)、班布特罗(bambuterol)、比托特罗(bitolterol)、溴沙特罗(broxaterol)、卡布特罗(carbuterol)、克伦特罗(clenbuterol)、多培沙明(dopexamine)、非诺特罗(fenoterol)、福莫特罗(formoterol)、海索那林(hexoprenaline)、异丁特罗(ibuterol)、异丙肾上腺素(isoprenaline)、马布特罗(mabuterol)、美卢君(meluadrine)、诺罗米罗(nolomirole)、奥西那林(orciprenaline)、吡布特罗(pirbuterol)、丙卡特罗(procaterol)、瑞普特罗(reproterol)、利托君(ritodrine)、利米特罗(rimoterol)、沙丁胺醇(salbutamol)、沙美特罗(salmeterol)、西贝奈迪(sibenadet)、磺酰特罗(sulfonterol)、特布他林(terbutaline)、妥洛特罗(tulobuterol)、维兰特罗(vilanterol)、殴达特罗(olodaterol)、KUL-1248、LAS-100977、卡莫特罗(carmoterol)和茚达特罗(indacaterol)。优选地,所述β2肾上腺素能激动剂为长效β2肾上腺素能激动剂,例如,其选自游离形式或药学上可接受的盐的形式的福莫特罗、沙美特罗、卡莫特罗、卡莫特罗、殴达特罗、LAS-100977和茚达特罗。
可与本发明的阿地铵结合的PDE4抑制剂包括登布茶碱(denbufylline)、咯利普兰(rolipram)、西潘茶碱(cipamfylline)、阿罗茶碱(arofylline)、非明司特(filaminast)、吡拉米司特(piclamilast)、美索普兰(mesopram)、盐酸屈他维林(drotaverinehydrochloride)、利米司特(lirimilast)、罗氟司特(roflumilast)、西洛司特(cilomilast)、6-[2-(3,4-二乙氧基苯基)噻唑-4-基]吡啶-2-羧酸、(R)-(+)-4-[2-(3-环戊氧基-4-甲氧基苯基)-2-苯乙基]吡啶、N-(3,5-二氯-4-吡啶基)-2-[1-(4-氟苄基)-5-羟基-1H-吲哚-3-基]-2-氧代乙酰胺、9-(2-氟苄基)-N6-甲基-2-(三氟甲基)腺嘌呤、N-(3,5-二氯-4-吡啶基)-8-甲氧基喹啉-5-羧酰胺、N-[9-甲基-4-氧代-1-苯基-3,4,6,7-四氢吡咯[3,2,1-jk][1,4]苯二氮-3(R)-基]吡啶-4-羧酰胺、3-[3-(环戊氧基)-4-甲氧基苄基]-6-(乙氨基)-8-异丙基-3H-嘌呤盐酸盐、4-[6,7-二乙氧基-2,3-双(羟甲基)萘-1-基]-1-(2-甲氧基乙基)吡啶-2(1H)-酮、2-甲酯基-4-氰基-4-(3-环丙基甲氧基-4-二氟甲氧基苯基)环己-1-酮、顺[4-氰基-4-(3-环丙基甲氧基-4-二氟甲氧基苯基)环己-1-醇、ONO-6126(Eur Respir J 2003,22(Suppl.45):Abst 2557)及PCT专利申请WO03/097613和PCT/EP03/14722和西班牙专利申请P200302613中要求保护的化合物。
用于本发明的阿地铵可通过任何适宜的途径给药以提供局部抗毒蕈碱作用。其优选以例如粉末、喷雾或气雾形式,优选以干粉形式通过吸入给药。包含阿地铵的药物组合物可用医学领域中已知的常规稀释剂或赋形剂和技术来制备。
用于以干粉形式通过吸入给药的药剂需具有受控的粒径。吸入至支气管系统的最佳粒径通常为1-10μm、优选2-5μm。粒径超过20μm的颗粒被吸入时通常太大以致于不能达到小的气道。为了达到所述粒径,可通过常规方法,例如通过微粉化或超临界流体技术来减小所产生的活性成分的尺寸。所需级分可以通过风选或风筛而分离。优选地,所述颗粒为晶体。
由于微粉化粉末的流动性差且极易团聚,因此难以使用微粉化粉末实现高剂量重复性。为了提高干粉组合物的效能,所述颗粒在吸入器中时应当较大,但是当其被送至呼吸道时应当较小。因此,一般使用赋形剂,例如单糖、二糖、多糖或者糖醇,例如乳糖、甘露醇或葡萄糖。所述赋形剂的粒径通常会远大于本发明吸入药剂的粒径。当所述赋形剂是乳糖时,其通常会以例如平均粒径为20-1000μm,优选90-150μm的乳糖颗粒存在,优选为晶体α-乳糖一水合物。在一个实施方案中,用于本发明的制剂的乳糖颗粒的d10为90-160μm,d50为170-270μm且d90为290-400μm。
适合用于本发明的乳糖材料可市购自,例如DMW Intemacional(Respitose GR-001、Respitose SV-001、Respitose SV-003);Meggle(Capsulae 60、Inhalac 70、Capsulae60INH);和Borculo Domo(Lactohale 100-200、Lactohale 200-300、Lactohale 100-300)。
乳糖颗粒与阿地铵的重量比取决于所使用的吸入装置,但是其通常为例如5∶1至200∶1,例如50∶1至150∶1,例如60-70∶1。
在优选的实施方案中,阿地铵以适于通过干粉吸入器给药的、阿地溴铵与乳糖混合的干粉制剂形式给药,阿地溴铵与乳糖的重量比为1∶50至1∶150,其中阿地铵颗粒的平均粒径为直径2至5μm,例如直径小于3μm;乳糖颗粒的d10为90-160μm,d50为170-270μm且d90为290-400μm。
通过吸入局部递送至肺的干粉组合物可以存在于例如明胶胶囊和药筒中或存在于例如层压铝箔的泡罩中,以用于在吸入器或吹入器中使用。每个胶囊或药筒一般可含有0.001-50mg,更优选0.01-5mg的活性成分或等同量的其药学上可接受的盐。或者,所述活性成分可以以无赋形剂的形式存在。
制剂的包装可以适用于单位剂量给药或多剂量递送。对于多剂量递送的情况,所述制剂可被预计量或在使用时计量。因此,干粉吸入器被分为三类:(a)单剂量装置;(b)多个单位剂量装置和(c)多剂量装置。
阿地铵优选用多剂量吸入器给药,更优选用(正式名称为NovolizerSD2FL)给药,其描述于以下专利申请中:WO97/000703、WO03/000325和WO2006/008027。
剂量会根据例如个体、给药方式和给药频率、待治疗的病症的性质和严重程度而变化。对于70kg的成年人,其每日剂量通常可以为例如约100-1000微克用于吸入的干粉形式的活性试剂的量级。
实施例1
在IIa期的随机、双盲、交叉试验中,中度至重度COPD患者接受400微克阿地铵,每日两次(早上9点;夜间9点)和安慰剂15天,在治疗期之间有9-15天的清洗期(washout)。
睡眠质量根据患者日志卡上的每日记录,按照如下标准使用0-4分进行评估:
0 | 无觉醒 |
1 | 早醒或在夜间醒来一次 |
2 | 早醒或在夜间醒来两次或多于两次 |
3 | 在夜间大多时候是醒着的 |
4 | 患者根本不能入睡 |
用阿地铵治疗的患者与未经治疗的患者相比显示出睡眠质量的显著改善。
实施例2
在双盲、随机、安慰剂对照的III期试验中,在COPD患者的每日进行两次阿地溴铵治疗期间,评估了睡眠质量和救援药物的使用。
向FEV1/FVC<70%的COPD患者随机(1∶1∶1)给药阿地铵200微克、400微克或安慰剂。使用电子日志和调查问卷每日报告睡眠质量,其评估了症状频率和严重程度及其对晨间活动的影响。还评估了救援药物的使用。
在第12周,阿地铵与安慰剂相比显著改善了睡眠质量。200微克和400微克阿地铵显著地降低了夜间呼吸急促和咳嗽的严重程度、醒来频率和再次入睡的困难程度。此外,还减少了痰液的产生和救援药物的使用。
两种阿地铵剂量还显著地降低了清晨呼吸急促的严重程度并降低了呼吸急促和咳嗽对晨间活动的影响。
实施例3
在IIa期的随机、双盲、双模拟、交叉试验中,中度至重度COPD患者接受吸入型阿地铵400μg BID(每日两次)、噻托铵18μg QD和安慰剂15天,在治疗期之间具有9-15天清洗期。
在患者日志卡上每日记录睡眠困难的发生率。与实施例1相同,分数从代表无睡眠困难的0分至代表睡眠困难严重程度递增的1-4分。然后测量由每种治疗所产生的相对于本底值的分数变化。
用噻托铵治疗的患者的平均分(+/-SEM)为-0.011(0.091),该分数实际上与本底值相同并且非常接近用安慰剂治疗的患者中观察到的分数0.061(0.088)。这两组分数在统计学上没有显著性差异(p>0.05)。相对而言,用阿地铵治疗的患者的分数为-0.123(0.089)。此情况下,在与安慰剂相比存在统计学上的显著差异(p<0.05)。
这些第IIa期结果证明,当用目前市场上的对照抗胆碱能药物噻托铵治疗患者时,未观察到由阿地铵产生的睡眠质量的显著改善。因此,阿地铵这种预料不到的效果是非显而易见的,具备创造性。
Claims (9)
1.阿地铵或其任何立体异构体或立体异构体混合物或其药学上可接受的盐或溶剂合物,用于改善呼吸系统疾病患者的睡眠质量的用途。
2.权利要求1的用于所述用途的阿地铵,其中所述阿地铵为阿地溴铵的形式。
3.权利要求1或2的用于所述用途的阿地铵,其中所述呼吸系统疾病患者患有哮喘或慢性阻塞性肺病(COPD)。
4.前述权利要求中任一项的用于所述用途的阿地铵,其中所述阿地铵为适于吸入的干粉制剂形式。
5.权利要求4的用于所述用途的干粉制剂的阿地铵,每次吸入提供计量标称剂量相当于100至1000微克阿地溴铵、更优选200或400微克阿地溴铵的阿地铵。
6.前述权利要求中任一项的用于所述用途的阿地铵,其中阿地铵为每日给药一次或多次,优选每日给药两次。
7.前述权利要求中任一项的用于所述用途的阿地铵,其中阿地铵与治疗有效量的皮质类固醇、β-肾上腺素能激动剂和/或PDE4抑制剂共同给药。
8.前述权利要求中任一项的用于所述用途的阿地铵,其中睡眠质量通过减少以下一项或多项和/或通过增加总睡眠时间来改善:
a)入睡前的等待时间
b)觉醒总次数
b)早醒
c)维持睡眠的难度
d)浅睡眠
e)失眠
f)日间嗜睡或疲劳
g)早晨期间活动限制。
9.药物组合物,包含如前述权利要求中任一项所定义的用于改善如前述权利要求中任一项所限定的呼吸系统疾病患者的睡眠质量的阿地铵。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11382114.4 | 2011-04-15 | ||
EP11382114A EP2510928A1 (en) | 2011-04-15 | 2011-04-15 | Aclidinium for use in improving the quality of sleep in respiratory patients |
US201161497771P | 2011-06-16 | 2011-06-16 | |
US61/497,771 | 2011-06-16 | ||
CN201280018637.2A CN103476412B (zh) | 2011-04-15 | 2012-04-11 | 用于改善呼吸系统疾病患者睡眠质量的阿地铵 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280018637.2A Division CN103476412B (zh) | 2011-04-15 | 2012-04-11 | 用于改善呼吸系统疾病患者睡眠质量的阿地铵 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107050024A true CN107050024A (zh) | 2017-08-18 |
Family
ID=44558460
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611019750.9A Pending CN107050024A (zh) | 2011-04-15 | 2012-04-11 | 用于改善呼吸系统疾病患者睡眠质量的阿地铵 |
CN201280018637.2A Active CN103476412B (zh) | 2011-04-15 | 2012-04-11 | 用于改善呼吸系统疾病患者睡眠质量的阿地铵 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280018637.2A Active CN103476412B (zh) | 2011-04-15 | 2012-04-11 | 用于改善呼吸系统疾病患者睡眠质量的阿地铵 |
Country Status (30)
Country | Link |
---|---|
US (2) | US20140100246A1 (zh) |
EP (2) | EP2510928A1 (zh) |
JP (1) | JP6322570B2 (zh) |
KR (1) | KR20140007929A (zh) |
CN (2) | CN107050024A (zh) |
AR (1) | AR085998A1 (zh) |
AU (1) | AU2012241858A1 (zh) |
BR (1) | BR112013024791A2 (zh) |
CA (1) | CA2826188A1 (zh) |
CL (1) | CL2013002996A1 (zh) |
CR (1) | CR20130532A (zh) |
CY (1) | CY1118786T1 (zh) |
DK (1) | DK2696871T3 (zh) |
EA (1) | EA201301168A1 (zh) |
ES (1) | ES2610104T3 (zh) |
GT (1) | GT201300249A (zh) |
HR (1) | HRP20170248T1 (zh) |
HU (1) | HUE031442T2 (zh) |
IL (1) | IL227666A0 (zh) |
LT (1) | LT2696871T (zh) |
ME (1) | ME02610B (zh) |
MX (1) | MX2013011772A (zh) |
PL (1) | PL2696871T3 (zh) |
PT (1) | PT2696871T (zh) |
RS (1) | RS55731B1 (zh) |
SG (1) | SG193912A1 (zh) |
SI (1) | SI2696871T1 (zh) |
SM (1) | SMT201700098B (zh) |
UY (1) | UY34016A (zh) |
WO (1) | WO2012140081A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
WO2015091288A1 (en) * | 2013-12-19 | 2015-06-25 | Almirall S.A. | Aclidinium for use in the treatment of cough |
WO2017108917A1 (en) * | 2015-12-22 | 2017-06-29 | Astrazeneca Ab | Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009112274A2 (en) * | 2008-03-13 | 2009-09-17 | Almirall, S.A. | Novel dosage and formulation |
Family Cites Families (178)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3091570A (en) | 1960-08-08 | 1963-05-28 | Lakeside Lab Inc | Antidepressant: 3-pyrrolidyl glycolates |
GB1219606A (en) | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
FR2414044A1 (fr) | 1978-01-10 | 1979-08-03 | Pharmindustrie | Nouveaux derives d'aza-1 bicyclo(2,2,2) octane, utilisables comme medicaments |
IT7920688V0 (it) | 1979-02-05 | 1979-02-05 | Chiesi Paolo Parma | Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore. |
IT1116047B (it) | 1979-04-27 | 1986-02-10 | Sigma Tau Ind Farmaceuti | Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma |
CY1492A (en) | 1981-07-08 | 1990-02-16 | Draco Ab | Powder inhalator |
FR2539135B1 (fr) | 1983-01-11 | 1986-02-28 | Essilor Int | Hydrogels de polyurethane et procede de fabrication |
US4570630A (en) | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
GB8334494D0 (en) | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
GB8613811D0 (en) | 1986-06-06 | 1986-07-09 | Phares Pharm Res Nv | Composition & method |
FI69963C (fi) | 1984-10-04 | 1986-09-12 | Orion Yhtymae Oy | Doseringsanordning |
US4675326A (en) | 1985-05-08 | 1987-06-23 | Gabriel Amitai | Bisquaternary antidotes |
US4855290A (en) | 1985-05-10 | 1989-08-08 | State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research | Derivatives of quinuclidine |
GB8718345D0 (en) | 1987-08-03 | 1987-09-09 | Fordonal Sa | N-substituted benzamides |
US4843074A (en) | 1988-05-17 | 1989-06-27 | Marion Laboratories, Inc. | 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts |
DE3927170A1 (de) | 1989-08-17 | 1991-02-21 | Boehringer Ingelheim Kg | Inhalator |
US5290815A (en) | 1989-09-07 | 1994-03-01 | Glaxo Group Limited | Treatment of inflammation and allergy |
DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
US5610163A (en) | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
GB8923590D0 (en) | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
IT1237118B (it) | 1989-10-27 | 1993-05-18 | Miat Spa | Inalatore multidose per farmaci in polvere. |
GB9001635D0 (en) | 1990-01-24 | 1990-03-21 | Ganderton David | Aerosol carriers |
US5201308A (en) | 1990-02-14 | 1993-04-13 | Newhouse Michael T | Powder inhaler |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
SG45171A1 (en) | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
GB9015522D0 (en) | 1990-07-13 | 1990-08-29 | Braithwaite Philip W | Inhaler |
WO1992003175A1 (en) | 1990-08-11 | 1992-03-05 | Fisons Plc | Inhalation device |
US5507281A (en) | 1990-08-30 | 1996-04-16 | Boehringer Ingelheim Kg | Device for initiating a mechanical switching operation in synchronism with the breathing |
DE4027391A1 (de) | 1990-08-30 | 1992-03-12 | Boehringer Ingelheim Kg | Treibgasfreies inhalationsgeraet |
WO1992004346A1 (en) | 1990-09-06 | 1992-03-19 | Pfizer Limited | Antimuscarinic bronchodilators |
US5091528A (en) | 1990-09-12 | 1992-02-25 | Allergan, Inc. | 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents |
ATE164525T1 (de) | 1990-09-26 | 1998-04-15 | Pharmachemie Bv | Inhalator mit einem reservoir für mehrere dosierte inhalationsmittel, mit transportvorrichtung und mit wirbelkammer |
GB9026025D0 (en) | 1990-11-29 | 1991-01-16 | Boehringer Ingelheim Kg | Inhalation device |
US5290539A (en) | 1990-12-21 | 1994-03-01 | Minnesota Mining And Manufacturing Company | Device for delivering an aerosol |
EP0504112A3 (en) | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
DE4108393A1 (de) | 1991-03-15 | 1992-09-17 | Boehringer Ingelheim Kg | Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln |
AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
US6299863B1 (en) | 1992-04-03 | 2001-10-09 | Sepracor Inc. | Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy |
GB9119705D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic compounds |
DE4239402A1 (de) | 1992-11-24 | 1994-05-26 | Bayer Ag | Pulverinhalator |
KR100312357B1 (ko) | 1992-12-09 | 2002-04-24 | 데이비드 이. 프랭크하우저 | 안정화된약제의에어로졸용액제제 |
MY115140A (en) | 1992-12-18 | 2003-04-30 | Schering Corp | Inhaler for powdered medications |
WO1995021820A1 (fr) | 1994-02-10 | 1995-08-17 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveau derive du carbamate et composition correspondante |
GB9404945D0 (en) | 1994-03-15 | 1994-04-27 | Glaxo Group Ltd | Pharmaceutical composition |
US5569447A (en) | 1994-04-19 | 1996-10-29 | The United States Of America Represented By The Secretary Department Of Health And Human Services | Stannylated 3-quinuclidinyl benzilates and methods of preparing radiohalogenated derivatives |
JP3545414B2 (ja) | 1994-07-29 | 2004-07-21 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | 架橋結合された粘弾性高分子材料に硬化可能なシロップ |
GB9426252D0 (en) | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
NO2005012I1 (no) | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
NZ306280A (en) | 1995-04-14 | 1999-07-29 | Glaxo Wellcome Inc | Metered dose inhaler for salmeterol |
CA2378713C (en) | 1995-06-21 | 2003-08-12 | Asta Medica Aktiengesellschaft | Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments |
AU6392496A (en) | 1995-06-29 | 1997-01-30 | Mcneil-Ppc, Inc. | The combination of topical nasal antihistamines and topical nasal steroids |
DE19528145A1 (de) | 1995-08-01 | 1997-02-06 | Boehringer Ingelheim Kg | Neue Arzneimittel und ihre Verwendung |
DE19536902A1 (de) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
US5846983A (en) | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US5824669A (en) | 1996-03-22 | 1998-10-20 | Nitromed, Inc. | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
US6150415A (en) | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
US5885834A (en) | 1996-09-30 | 1999-03-23 | Epstein; Paul M. | Antisense oligodeoxynucleotide against phosphodiesterase |
SE9603669D0 (sv) | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
FR2756739B1 (fr) | 1996-12-05 | 2000-04-28 | Astra Ab | Nouvelle formulation de budesonide |
US6495167B2 (en) | 1997-03-20 | 2002-12-17 | Schering Corporation | Preparation of powder agglomerates |
GB9807232D0 (en) | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
US6423298B2 (en) | 1998-06-18 | 2002-07-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical formulations for aerosols with two or more active substances |
ES2211108T3 (es) | 1998-06-18 | 2004-07-01 | Boehringer Ingelheim Pharmaceuticals Inc. | Formulaciones farmaceuticas para aerosoles con dos o mas sustancias activas. |
ITMI981671A1 (it) | 1998-07-21 | 2000-01-21 | Zambon Spa | Derivati ftalazinici inibitori della fosfodisterasi 4 |
US6475467B1 (en) | 1998-08-04 | 2002-11-05 | Jago Research Ag | Medicinal aerosol formulations |
US5962505A (en) | 1998-08-31 | 1999-10-05 | Bobrove; Arthur M. | Method for treating hot flashes in humans |
DE19847968A1 (de) | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen |
GB9902689D0 (en) | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
US20040002548A1 (en) | 1999-05-12 | 2004-01-01 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
US7214687B2 (en) | 1999-07-14 | 2007-05-08 | Almirall Ag | Quinuclidine derivatives and medicinal compositions containing the same |
SE9902935D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
GB9928311D0 (en) | 1999-11-30 | 2000-01-26 | Novartis Ag | Organic compounds |
US6410563B1 (en) | 1999-12-22 | 2002-06-25 | Merck Frosst Canada & Co. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
FR2803378B1 (fr) | 1999-12-29 | 2004-03-19 | Valeo Climatisation | Echangeur de chaleur a tubes a plusieurs canaux, en particulier pour vehicule automobile |
EP1258253A1 (en) | 2000-01-28 | 2002-11-20 | Asahi Kasei Kabushiki Kaisha | Novel remedies with the use of beta3 agonist |
IL150486A0 (en) | 2000-01-31 | 2002-12-01 | Pfizer Prod Inc | Pyrimidine carboxamides useful as inhibitors of pde4 isozymes |
CA2404226A1 (en) | 2000-03-23 | 2001-09-27 | Takeda Chemical Industries, Ltd. | Furoisoquinoline derivatives, process for producing the same and use thereof |
GB0008485D0 (en) | 2000-04-07 | 2000-05-24 | Glaxo Group Ltd | Pharmaceutical compositions |
GB0009606D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Therapeutic combinations |
GB0009583D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
GB0009592D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory combinations |
GB0009605D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medicaments |
GB0012261D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel process |
ME00220B (me) | 2000-05-22 | 2010-10-10 | Chiesi Farm Spa | Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom |
US20020052312A1 (en) | 2000-05-30 | 2002-05-02 | Reiss Theodore F. | Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists |
AR029984A1 (es) | 2000-07-27 | 2003-07-23 | Smithkline Beecham Corp | Metodo para reducir las exacerbaciones asociadas copd ambito |
US6852728B2 (en) | 2000-10-14 | 2005-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them |
US6706726B2 (en) | 2000-10-14 | 2004-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anticholinergics which may be used as medicaments as well as processes for preparing them |
US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
US20030158196A1 (en) | 2002-02-16 | 2003-08-21 | Boehringer Ingelheim Pharma Gmbh Co. Kg | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors |
DE10110772A1 (de) | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
CA2733294C (en) | 2000-10-31 | 2011-12-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical combination of a tiotropium salt and ciclesonide |
US20020193393A1 (en) | 2001-03-07 | 2002-12-19 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
US20020183292A1 (en) | 2000-10-31 | 2002-12-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and corticosteroids |
US20020151541A1 (en) | 2000-10-31 | 2002-10-17 | Michel Pairet | Pharmaceutical compositions containing tiotropium salts and antihistamines and their use |
DE10062712A1 (de) | 2000-12-15 | 2002-06-20 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden |
US20020137764A1 (en) | 2000-10-31 | 2002-09-26 | Karin Drechsel | Inhalable formulation of a solution containing a tiotropium salt |
US20020122773A1 (en) | 2000-12-20 | 2002-09-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and dopamine agonists |
US6620438B2 (en) | 2001-03-08 | 2003-09-16 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists |
US6608054B2 (en) | 2001-03-20 | 2003-08-19 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics and endothelin antagonists |
DE10056104A1 (de) | 2000-11-13 | 2002-05-23 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols |
US20020193392A1 (en) | 2000-11-13 | 2002-12-19 | Christel Schmelzer | Pharmaceutical compositions based on tiotropium salts of salts of salmeterol |
US20100310477A1 (en) | 2000-11-28 | 2010-12-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg. | Pharmaceutical compositions based on anticholingerics and additional active ingredients |
PE20020719A1 (es) | 2000-12-22 | 2002-10-11 | Almirall Prodesfarma Ag | Derivados de carbamato de quinuclidina como agentes antimuscarinicos m3 |
AU2002238471B2 (en) | 2000-12-28 | 2007-06-28 | Almirall, S.A. | Quinuclidine derivatives and their use as M3 antagonists |
DE10104370A1 (de) | 2001-02-01 | 2002-08-08 | Boehringer Ingelheim Pharma | Arzneimittelkompositionen mit geringeren Nebenwirkungen |
US20020189610A1 (en) | 2001-02-01 | 2002-12-19 | Karl-Heinz Bozung | Pharmaceutical compositions containing an ipratropium salt and a betamimetic |
US20020179087A1 (en) | 2001-02-01 | 2002-12-05 | Karl-Heinz Bozung | Pharmaceutical compositions containing an oxitropium salt and a betamimetic |
DE10104367A1 (de) | 2001-02-01 | 2002-08-08 | Boehringer Ingelheim Pharma | Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US20030216329A1 (en) | 2001-04-24 | 2003-11-20 | Robinson Cynthia B. | Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s) |
EP1397135B1 (en) | 2001-05-25 | 2006-12-06 | Boehringer Ingelheim Pharma GmbH & Co.KG | Combination of a pde4 inhibitor and tiotropium or derivative thereof for treating obstructive airways |
US20040147544A1 (en) | 2001-05-25 | 2004-07-29 | Michael Yeadon | Pde4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases |
GB0115181D0 (en) | 2001-06-20 | 2001-08-15 | Glaxo Group Ltd | Novel use |
DE10129703A1 (de) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
DE10130371A1 (de) | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
US20030018019A1 (en) | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
GB0118373D0 (en) | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
US6680345B2 (en) | 2001-09-14 | 2004-01-20 | Boehringer Ingelheim Pharma Kg | Salicylic acid salts of salmeterol |
US6919325B2 (en) | 2001-09-14 | 2005-07-19 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts |
CA2459493C (en) | 2001-09-14 | 2011-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New pharmaceutical compositions for inhalation |
US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
US6974803B2 (en) | 2001-12-06 | 2005-12-13 | Pfizer Inc | Pharmaceutical combination |
DE10202940A1 (de) | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
US6790856B2 (en) | 2002-01-31 | 2004-09-14 | Boehringer Ingelheim Pharma Kg | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments |
GB0202635D0 (en) | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative |
ME00077B (me) | 2002-03-01 | 2010-06-10 | Chiesi Farm Spa | Formoterol najfiniji preparat |
US6756508B2 (en) | 2002-03-04 | 2004-06-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Cinnamic acid salts, processes for their preparation, and their use as medicaments |
DE10216429A1 (de) | 2002-04-12 | 2003-10-23 | Boehringer Ingelheim Pharma | Arzneimittel enthaltend Steroide und ein neues Anticholinergikum |
DE10216333A1 (de) | 2002-04-13 | 2003-10-30 | Boehringer Ingelheim Pharma | Neue Carbonsäureester mit anticholonerger Wirksamkeit, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7094788B2 (en) | 2002-04-13 | 2006-08-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions |
ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
ES2195785B1 (es) | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
RU2316318C2 (ru) | 2002-05-17 | 2008-02-10 | Новартис Аг | Фармацевтическая композиция, включающая ингибитор ренина, блокатор кальциевых каналов и диуретик |
ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
US20040058950A1 (en) | 2002-07-09 | 2004-03-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
ES2211315B1 (es) | 2002-11-12 | 2005-10-16 | Almirall Prodesfarma, S.A. | Nuevos compuestos triciclicos. |
CA2506949A1 (en) | 2002-11-27 | 2004-06-10 | Altana Pharma Ag | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia |
ES2211344B1 (es) | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
DE10307759B3 (de) | 2003-02-19 | 2004-11-18 | Schering Ag | Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel |
EP1452179A1 (en) | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
US20040184995A1 (en) | 2003-03-17 | 2004-09-23 | Yamanouchi Pharmaceutical Co., Ltd. | Novel dry powder inhalation for lung-delivery and manufacturing method thereof |
CA2519682A1 (en) | 2003-03-28 | 2004-10-07 | Altana Pharma Ag | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
MXPA05010160A (es) | 2003-03-28 | 2005-11-16 | Altana Pharma Ag | Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias. |
US20050026948A1 (en) | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
CA2534125A1 (en) | 2003-07-29 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders |
BRPI0413054A (pt) | 2003-07-29 | 2006-10-17 | Boehringer Ingelheim Int | combinação de um anticolinérgico e um esteróide e seu uso no tratamento de distúrbios respiratórios por inalação |
US20050026886A1 (en) | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor |
WO2005014044A1 (en) | 2003-07-29 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising betamimetics and an anticholinergic |
US20050026887A1 (en) | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a steroid |
ATE526967T1 (de) | 2003-07-31 | 2011-10-15 | Boehringer Ingelheim Int | Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum |
US20050025718A1 (en) | 2003-07-31 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
DE10347994A1 (de) | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Wässrige Aerosol-Zubereitung |
ES2232306B1 (es) | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
WO2005074918A1 (en) | 2004-02-06 | 2005-08-18 | Benzstrasse 1 D-61352 Bad Homburd | The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd |
CN101518532A (zh) | 2004-02-06 | 2009-09-02 | Meda制药有限及两合公司 | 用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合 |
WO2005074900A2 (en) | 2004-02-06 | 2005-08-18 | Meda Pharma Gmbh & Co. Kg | NOVEL COMBINATION OF ANTICHOLINERGIC AND β MIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES |
ES2239546B1 (es) | 2004-03-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos esteres de quinuclidina cuaternizados. |
DE102004016179A1 (de) | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Verbindungen zur Behandlung von proliferativen Prozessen |
DE602005018969D1 (de) | 2004-05-31 | 2010-03-04 | Almirall Sa | Zusammensetzungen mit Antimuskarin-Wirkstoffen und Corticosteroiden |
ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
RU2413544C2 (ru) | 2004-07-16 | 2011-03-10 | Алмиралл, С.А. | Ингалятор и картридж для лекарственного порошкового препарата и способ работы ингалятора |
WO2006105401A2 (en) | 2005-03-30 | 2006-10-05 | Schering Corporation | Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist |
ES2298049B1 (es) | 2006-07-21 | 2009-10-20 | Laboratorios Almirall S.A. | Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano. |
GB0702457D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination 666 |
KR20090121338A (ko) | 2007-02-19 | 2009-11-25 | 씨아이피엘에이 엘티디. | 두 개 이상의 기관지확장제 또는 기관지확장제와 코르티코스테로이드의 약제학적 조합 |
MY153408A (en) | 2007-02-21 | 2015-02-13 | Almirall Sa | Novel methods |
EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
EP2666465A1 (en) | 2012-05-25 | 2013-11-27 | Almirall, S.A. | Novel dosage and formulation |
ES2917879T3 (es) | 2012-12-17 | 2022-07-12 | Almirall Sa | Nuevo uso de aclidinio |
-
2011
- 2011-04-15 EP EP11382114A patent/EP2510928A1/en not_active Withdrawn
-
2012
- 2012-04-11 LT LTEP12712699.3T patent/LT2696871T/lt unknown
- 2012-04-11 ME MEP-2017-39A patent/ME02610B/me unknown
- 2012-04-11 PL PL12712699T patent/PL2696871T3/pl unknown
- 2012-04-11 BR BR112013024791A patent/BR112013024791A2/pt not_active IP Right Cessation
- 2012-04-11 SG SG2013069760A patent/SG193912A1/en unknown
- 2012-04-11 MX MX2013011772A patent/MX2013011772A/es not_active Application Discontinuation
- 2012-04-11 EP EP12712699.3A patent/EP2696871B1/en active Active
- 2012-04-11 US US14/111,211 patent/US20140100246A1/en not_active Abandoned
- 2012-04-11 RS RS20170159A patent/RS55731B1/sr unknown
- 2012-04-11 DK DK12712699.3T patent/DK2696871T3/en active
- 2012-04-11 SI SI201230867A patent/SI2696871T1/sl unknown
- 2012-04-11 CA CA2826188A patent/CA2826188A1/en not_active Abandoned
- 2012-04-11 PT PT127126993T patent/PT2696871T/pt unknown
- 2012-04-11 HU HUE12712699A patent/HUE031442T2/en unknown
- 2012-04-11 CN CN201611019750.9A patent/CN107050024A/zh active Pending
- 2012-04-11 CN CN201280018637.2A patent/CN103476412B/zh active Active
- 2012-04-11 AU AU2012241858A patent/AU2012241858A1/en not_active Abandoned
- 2012-04-11 KR KR1020137025417A patent/KR20140007929A/ko not_active Application Discontinuation
- 2012-04-11 UY UY0001034016A patent/UY34016A/es unknown
- 2012-04-11 JP JP2014504296A patent/JP6322570B2/ja active Active
- 2012-04-11 EA EA201301168A patent/EA201301168A1/ru unknown
- 2012-04-11 WO PCT/EP2012/056575 patent/WO2012140081A1/en active Application Filing
- 2012-04-11 ES ES12712699.3T patent/ES2610104T3/es active Active
- 2012-04-12 AR ARP120101254A patent/AR085998A1/es unknown
-
2013
- 2013-07-25 IL IL227666A patent/IL227666A0/en unknown
- 2013-10-15 CR CR20130532A patent/CR20130532A/es unknown
- 2013-10-15 GT GT201300249A patent/GT201300249A/es unknown
- 2013-10-15 CL CL2013002996A patent/CL2013002996A1/es unknown
-
2016
- 2016-05-23 US US15/161,531 patent/US9737520B2/en active Active
-
2017
- 2017-02-13 CY CY20171100193T patent/CY1118786T1/el unknown
- 2017-02-14 SM SM201700098T patent/SMT201700098B/it unknown
- 2017-02-16 HR HRP20170248TT patent/HRP20170248T1/hr unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009112274A2 (en) * | 2008-03-13 | 2009-09-17 | Almirall, S.A. | Novel dosage and formulation |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9737520B2 (en) | Aclidinium for use in improving the quality of sleep in respiratory patients | |
JP2005539046A (ja) | 特異的な抗コリン作用薬、β−2アゴニスト、および副腎皮質ステロイドを含む、治療薬および組成物 | |
JP2020023537A (ja) | Copdの治療のためのチオトロピウムブロミド、フォルモテロール及びブデソニドの組み合わせ | |
US20180000798A1 (en) | Use of aclidinium | |
WO2024033625A1 (en) | Ensifentrine (rpl-554) for increasing trough lung function | |
TW201302195A (zh) | 阿地銨(aclidinium)之新用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170818 |
|
WD01 | Invention patent application deemed withdrawn after publication |